NYSE - Delayed Quote USD

Merck & Co., Inc. (MRK)

126.94

+1.16

(+0.92%)

At close: April 22 at 4:00 PM EDT

127.49

+0.55

(+0.43%)

After hours: April 22 at 7:57 PM EDT

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Zacks 11 hours ago

MRK
+0.92%
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 14 hours ago

LLY
+0.69%
EXAS

NBIX
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their...

Simply Wall St. yesterday

MRK
+0.92%
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic

CNW Group 3 days ago

MRK
+0.92%
13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]

Insider Monkey 4 days ago

^GSPC

^VIX

TSM
Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...

Simply Wall St. 5 days ago

MRK
+0.92%
3 Dow Stocks to Buy Now: Q2 Edition

Let’s be real – the narrative for Dow stocks to buy now tends to be one of relative safety. What are the chances that the 30 companies of the Dow Jones Industrial Average will be the most exciting ideas of any given year? I’d say quite low. However, circumstances can always change, as we’ve seen in the geopolitical environment. Following Iran launching missiles against Israel in retaliation for allegedly bombing its embassy in Syria, the world is on edge regarding Israel’s likely response. What

InvestorPlace 6 days ago

CAT

MRK
+0.92%
CVX
+1.20%
10 Best Low Volatility ETFs To Buy

In this article, we discuss 10 best low volatility ETFs to buy. If you want to skip our discussion on low volatility investments, head over to 5 Best Low Volatility ETFs To Buy. What is Low Volatility Investing? Low volatility investing refers to an investment strategy where a stock portfolio is less volatile in terms […]

Insider Monkey 7 days ago

MSFT

STLAM.MI

MRK
+0.92%
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla

InvestorPlace 10 days ago

MRK
+0.92%
NVO

APM
Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Merck's (NYSE:MRK) stock is up by 7.0% over the past three months. However, its weak financial performance indicators...

Simply Wall St. 11 days ago

MRK
+0.92%
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Zacks 12 days ago

MRNA

ADMA

ANIP
Company News for Apr 10, 2024

Companies in The News Are: MRNA, MRK, COIN, BN, NEOG

Zacks 12 days ago

MRNA

NEOG

COIN
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started. With compounding interest and dividend growth, investors who take investing and saving for retirement seriously can become very profitable over a number of decades. Here are a number of stocks that provide investors with a fantastic start to a long-term investment portfolio for growth as well as overall income g

InvestorPlace 14 days ago

MRK
+0.92%
CMCSA

VICI
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden’s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country’s economic resilience, bolstered by substantial fiscal s

InvestorPlace 15 days ago

AMGN
+1.11%
HD
+0.22%
MRK
+0.92%
10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

Insider Monkey 16 days ago

LLY
+0.69%
NVO

VKTX
The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period

By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...

Simply Wall St. 16 days ago

MRK
+0.92%
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.

Zacks 17 days ago

MRK
+0.92%
Merck puts KRAS cancer drug competitor to the test

A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

BioPharma Dive 18 days ago

MRK
+0.92%
AMGN
+1.11%
CELG-RT
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).

Business Wire 18 days ago

MRK
+0.92%
Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) reachead $129.90 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.

Zacks 19 days ago

MRK
+0.92%

Performance Overview

Return	MRK	S&P 500
YTD	+17.18%	+5.05%
1-Year	+13.04%	+21.22%
3-Year	+84.18%	+20.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (MRK)

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

10 Best Performing Biotech ETFs in 2024

Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

13 Best Low Volatility Stocks to Buy According to Hedge Funds

Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

3 Dow Stocks to Buy Now: Q2 Edition

10 Best Low Volatility ETFs To Buy

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Company News for Apr 10, 2024

Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

10 Best Weight Loss Drug Stocks to Buy Now

The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck puts KRAS cancer drug competitor to the test

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Performance Overview